The Broken Contract Between Pharma Data Producers and Consumers

Walk into a data analytics team meeting at any mid-cap pharma organization and you will hear a version of the same conversation. A commercial analyst is frustrated because a field in a downstream sales report changed meaning last quarter without anyone telling her. A clinical data manager cannot reconcile a summary table with the underlying EDC extract. A pharmacovigilance data scientist has quietly stopped trusting the patient identifier column in a real-world data feed and is manually joining it against a lookup table that only she maintains.

None of these people have a written agreement with the teams producing their data. They have shared understandings, informal expectations, and the assumption that “someone will tell us if something changes.” What they actually have is what the modern data engineering community calls an implicit contract: a set of expectations that both parties would be embarrassed to write down, because the moment they are written down, everyone realizes how much of the current data flow is actually held together by tribal knowledge.

The problem is not new. Data quality issues in pharma have been well-documented for decades, and the industry has invested heavily in data governance, master data management, and data lineage tooling to address them. What is new is the volume, velocity, and consequence of downstream data consumption. When a clinical study report was the primary consumer of clinical data, the data flow was slow enough that human quality control could keep up. When the primary consumers include real-time dashboards, machine learning models feeding pharmacovigilance signal detection, and AI-assisted regulatory writing, the human-in-the-loop model breaks. The implicit contract cannot scale to what modern pharma is now asking its data platforms to do.

60%+ of FDA warning letters relate to data integrity issues3
60% of AI projects lacking AI-ready data will be abandoned by 20264
14x lower quality costs for pharma operational leaders using digital extensively5

Chad Sanderson, who has written more publicly about data contracts than anyone in the field, describes the shift bluntly: producers are shipping code, and their code changes break consumers who did not know the code was going to change1. In pharma, the code changing is not always application code. It is a lab instrument being reconfigured, a CRO switching EDC vendors mid-study, a manufacturing site upgrading its MES, or a commercial data provider adjusting how they define territory alignment. Each of these events has the same downstream signature: a producer changed something, a consumer downstream did not know, and a report, model, or regulatory submission is now wrong in ways that will only be discovered later, if at all.

The core insight: Data contracts do not solve every data problem in pharma. They solve one specific problem exceptionally well: the mismatch between what producers deliver and what consumers assumed they would receive. In pharma, that mismatch is where a disproportionate share of data integrity failures originate.

What a Data Contract Actually Is (in Pharma Terms)

Strip away the vendor marketing, and a data contract is a written agreement between the team producing a dataset and the teams consuming it. That agreement specifies what the dataset contains, how it is structured, what quality thresholds it meets, what SLAs the producer commits to, who owns the dataset, and how changes to any of the above will be communicated, tested, and approved. The contract is written in a format that can be enforced automatically, so violations do not depend on human vigilance to detect6.

For a pharma audience, the closest analog is the specification section of a Master Service Agreement with a CRO, translated into a machine-readable format and applied to internal data flows rather than external ones. The contract is not a general-purpose document. It is scoped to a specific dataset (or “data product” in mesh terminology), and it lives alongside the data itself, versioned and reviewed like any other regulated artifact.

The Six Components of a Data Contract

Schema

What the data looks like

Field names, data types, allowed values, nullability, primary keys, foreign key relationships. Machine-enforceable. Changes require a version bump.

Semantics

What the data means

Definitions for each field in business terms. What does “randomization_date” mean? What is included in “active_ingredient_amount”? The place where “we assumed X” gets written down.

Quality

What thresholds the data meets

Row counts, null rates, referential integrity, freshness. Producer commits to these; consumer is entitled to be alerted when they are breached.

SLA

Service level

How often the data updates, expected latency, uptime commitments, how quickly the producer will respond to a data incident.

Ownership

Who is responsible

Named producer team and specific data product owner. Named consumer teams. Escalation path when quality is breached or SLA is missed.

Change Protocol

How changes are managed

Notice period for schema changes, review and approval process, deprecation timelines, backward compatibility commitments. The section that prevents silent breakage.

The critical difference between a data contract and a traditional data specification is enforceability. A specification says what the data should look like; a contract wires up the checks that verify what the data actually looks like on every load, and generates an alert when reality drifts from the contract. In pharma terms, this is the difference between a quality specification and a quality control test. The specification without the test is aspirational. The contract with automated enforcement is operational7.

Sakara Digital perspective: The most common mistake we see in pharma data contract initiatives is treating the contract as a document rather than a control. If your data contract lives in Confluence and no one has wired it into your pipeline as an automated check, you have written a specification. That is a useful starting point, but it does not deliver the risk reduction the contract is supposed to provide. The contract must be enforced by tooling, not by trust.

Producer-Defined Versus Consumer-Defined Contracts

A recurring debate in the data engineering community is whether contracts should be defined by producers or by consumers. Sanderson has argued at length for consumer-defined contracts2, on the grounds that only consumers know what they actually need, and producers left to their own devices will write contracts that describe whatever the system happens to produce today, not what downstream users can rely on.

For pharma, the answer is usually somewhere in between. Producer-defined contracts are appropriate when the source system is a validated GxP system whose data model is already tightly specified by validation documentation. The contract is essentially a machine-readable extract of the validation package, and the producer team is the correct owner because they own the validated system. Consumer-defined contracts are appropriate for aggregated data products where multiple downstream teams have specific analytical needs, and the producer team may not know which fields matter to whom.

In practice, mature pharma data organizations use a hybrid model. Contracts on data products that come directly from validated source systems (LIMS extracts, EDC data, MES tables, ERP master data) are producer-defined and mirror the source system’s data dictionary. Contracts on curated data products that feed analytics, dashboards, and models are consumer-defined, with the curation team acting as producer on behalf of a consortium of downstream consumers.

The Cost of Operating Without Data Contracts in Regulated Environments

The financial case for data contracts in pharma is easier to make than in most industries because the downstream failures are more expensive. A broken dashboard at a consumer tech company is embarrassing. A broken data flow feeding pharmacovigilance signal detection at a pharma company can be a reportable safety event.

McKinsey’s analysis of pharma operational excellence shows a widening gap between digital leaders and laggards, with operational leaders achieving 14 times lower quality costs than peers5. The savings potential from manufacturing efficiency improvements across the industry has been estimated at roughly $150 billion annually, up from an earlier $50 billion estimate as digitization has advanced8. Both figures depend on data quality that most organizations do not currently have.

Gartner’s more recent work is even more pointed. In their 2025 assessment, 63% of organizations either do not have or are unsure whether they have the right data management practices to support AI, and they project that 60% of AI projects lacking AI-ready data will be abandoned by 20264. In pharma, “abandoned AI projects” is not just a productivity loss; it is a competitive gap that widens over time as leading peers ship the same use cases you gave up on.

The pattern we see in failed pharma AI projects: The model works in the lab. The training data is clean. The validation runs pass. Then the model goes into production and starts drifting almost immediately, because the upstream data producers who did not know they had consumers are shipping schema changes, definition changes, and quality regressions the model was never designed to tolerate. Without data contracts, no one is watching the interface between producer and consumer, and no one is on the hook for maintaining it.

The Regulatory Cost

Beyond the financial and productivity costs, the regulatory cost of poor data contracts is significant and rising. FDA has stated that over 60% of warning letters cite data integrity issues3. Draft EU GMP Chapter 4, published in July 2025, formally codifies ALCOA++ requirements into regulation11. ICH E6(R3), finalized in January 2025, establishes data governance requirements for clinical trials globally12. The EU AI Act imposes data quality and traceability requirements on high-risk AI systems, a category that includes many pharma AI applications9.

None of these regulatory frameworks explicitly require data contracts. But all of them require the kind of documented, traceable, controlled data flows that data contracts happen to deliver. If you were building the regulatory response from scratch today, you would build something that looked very much like a data contract.

A Practical Data Contract Template for Pharma

The following template is a starting point. It is deliberately simpler than what the data engineering literature would suggest, because pharma organizations do not need every capability the tooling vendors offer. What they need is a written, versioned, enforceable agreement covering the six components we outlined earlier. Below is a minimal viable structure that has held up in our client work.

Section 1: Identity and Ownership

The header of every data contract identifies the data product, its unique identifier, the producer team, the consumer teams, and the escalation contacts on both sides. Every named team includes an accountable individual, not just a mailing list. If you cannot name a specific person as the data product owner, you do not yet have a data product ready to be under contract.

Section 2: Schema Definition

The schema section defines every field: name, data type, allowed range or enumerated values, nullability, and primary/foreign key relationships. This section is machine-readable (typically YAML, JSON Schema, or Protobuf) so that it can be wired directly into automated validation checks on every load of the dataset. The schema is versioned. Additive changes (new nullable fields) can happen without a major version bump; breaking changes (renamed fields, removed fields, changed types) require a new version and a coordinated migration.

Section 3: Semantic Definitions

For every field, a plain-English definition of what the field means in business terms. This section is often longer than the schema section, and it is where the most tribal knowledge gets written down. Include: what the field represents, what values it can take and what they mean, any calculation logic if the field is derived, edge cases, and known limitations. This is the section that prevents downstream consumers from making incorrect assumptions about the semantics of the data.

Section 4: Quality Guarantees

The quality section specifies the thresholds the producer commits to meeting on every load. Typical checks include row count ranges, maximum null rates per column, referential integrity to reference tables, uniqueness constraints, distribution checks for numerical fields, and business-rule assertions (for example, “randomization_date is never earlier than screening_date”). Each check is documented with the threshold, the action taken when it fails (alert, block, quarantine), and the response SLA.

Section 5: Service Level Agreement

The SLA section commits to how often the data updates, how quickly after the source event the data becomes available, expected uptime, and how quickly the producer will respond to a reported data incident. Include the specific hours during which the SLA applies (a 24/7 SLA is much harder to meet than a “business hours” SLA and should only be committed to when the consumer actually needs it).

Section 6: Change Management Protocol

The change protocol section is the section that prevents silent breakage. Include: notice period for any schema change, the review and approval process, the deprecation timeline for retired fields, backward compatibility commitments, and the communication channel for change announcements. This is also the section that ties the data contract into your organization’s validated-system change control if the underlying source is a GxP system.

Change Type Notice Period Approval Required Consumer Action
Additive: new nullable field 2 weeks Producer team only None required
Additive: new required field 4 weeks Producer + affected consumers Update ingestion logic
Breaking: renamed or removed field 8 weeks minimum Producer + all consumers + governance Update ingestion; test in dev; migrate
Breaking: changed data type 8 weeks minimum Producer + all consumers + governance Update ingestion; test in dev; migrate
Semantic: changed field definition 6 weeks minimum Producer + all consumers + governance Review downstream logic; migrate if affected
SLA change 4 weeks Producer + all consumers Review dependencies; renegotiate if needed

How to Roll Out Data Contracts in a Regulated Setting

The rollout question is where most pharma data contract initiatives get stuck. The engineering-forward version of the answer says “start with your highest-value data products, write contracts, and enforce them in your pipeline.” That is correct but incomplete. In a regulated environment, the rollout has to respect three additional constraints: existing validated-system change control, the audit trail requirements that come with any new control, and the political reality that data producers do not typically volunteer to be held to standards they were not previously accountable for.

1

Discovery: identify your highest-consequence data flows

Before writing any contracts, map the data flows in your organization by consequence. Which datasets, if silently broken, would cause the biggest downstream problem? Regulatory submissions, pharmacovigilance signal detection, GxP manufacturing analytics, and safety data typically top the list. Rank ruthlessly. The first contracts should be on the highest-consequence flows, not the easiest.

2

Pilot: one data product, one contract, one consumer team

Pick a single data product with a single primary consumer. Work with the producer team to draft the contract from what the system currently delivers (not what it should ideally deliver). Wire the contract into automated checks that run on every load. Set the initial alert thresholds generously; you can tighten them as you learn what “normal” looks like. The pilot’s success criterion is not that the contract is perfect, but that both producer and consumer teams find it useful and are willing to be measured against it.

3

Governance integration: connect the contract to your change control

Before scaling beyond the pilot, connect the contract’s change protocol into your existing validated-system change control. If the source system is GxP-validated, changes to its data model already flow through your change control process. Your contract’s schema versioning and consumer notification should be triggered automatically by that same process, not run in parallel to it. This is where you avoid creating a shadow governance system that competes with the one that already exists.

4

Producer enablement: give producer teams the tooling they need

The single biggest reason data contract initiatives fail is that producer teams are asked to comply with contracts but not given the tooling to author them, test against them, or catch violations before they reach consumers. Invest in producer-side tooling: schema-authoring tools, contract test runners in the source system’s CI/CD pipeline, and visibility into contract violations. If a producer team cannot see when they are about to break a contract, they will break it.

5

Scale: expand to your top-10 data products in the first year

Once the pilot is stable and the change-control integration is working, scale to your top 10 highest-consequence data products in the first year. Do not try to contract every dataset. Data contracts are expensive to author and maintain; they earn their keep on the data flows where silent breakage would be costly. For lower-consequence flows, lighter-weight quality monitoring is often the right answer.

6

Institutional adoption: bake contracts into new data product creation

The end state is not “contracts on every legacy data flow.” It is “every new data product ships with a contract from day one.” Once the pattern is established on your top data products, the next phase is to make contract authoring part of the standard operating procedure for any new dataset that will be consumed by anyone outside the producing team.

What success looks like at 18 months: Your top 10-15 data products are under contract with automated enforcement. New data products created after the initial rollout ship with contracts from day one. Producer teams have adopted contract-first workflows and treat schema changes as a versioned engineering activity rather than an ad-hoc edit. Data incidents are detected at the producer boundary rather than in the consumer downstream, and the average time from breakage to detection has dropped from days to minutes.

Common Objections and How to Handle Them

Every data contract rollout in pharma encounters the same objections. Anticipating them and having crisp answers ready saves months of stalled progress.

“This is just governance by another name. We already have data governance.”

Most pharma organizations do have data governance, and most pharma data governance programs have not delivered the outcomes their sponsors expected. Traditional data governance sets policies, defines roles, and publishes standards. It rarely wires up automated enforcement, and it rarely produces artifacts that engineering teams can consume programmatically. Data contracts are the operational layer that translates governance intent into pipeline reality. They complement governance rather than replace it. If your governance program has policies about data quality, semantic clarity, and change management, data contracts are the mechanism that turns those policies into enforceable controls at the point where data actually moves.

“Our data producers will never agree to this.”

Sometimes true, and this is a legitimate concern. Producers who have operated under implicit contracts for years have every reason to resist being held to explicit standards. The countermove is not to force compliance; it is to make the contract obviously beneficial to the producer team. Producer teams that adopt contracts get: fewer 3 a.m. escalations about their data because consumers catch issues at ingestion; a clearer scope of accountability (they are responsible for meeting the contract, not for every downstream use of their data); and better visibility into who depends on what they produce. Selling the contract as a boundary-setter for producers, not just as a quality tool for consumers, is what unsticks these conversations.

“Our source system is GxP-validated. We cannot just add contracts on top of it.”

Correct, and this is where the integration with existing change control matters. You are not adding uncontrolled artifacts to a validated system. You are adding a downstream control that consumes what the validated system produces. The contract lives outside the validated boundary, in the analytics or data platform layer. Changes to the validated source system flow through their existing change control; the contract’s schema versioning is a consumer of that change control, not a parallel process. This is the same architectural pattern used for any downstream reporting or analytics system that sits on top of a GxP source.

“We do not have the tooling for this.”

Tooling is a legitimate concern but is not a blocker. In the last three years, the tooling ecosystem for data contracts has matured considerably. Established data quality platforms have added contract features. Open-source projects support schema-based contract enforcement. Modern data platforms (Databricks, Snowflake, and their peers) have native support for schema evolution controls that map cleanly to contract concepts. You do not need to build tooling; you need to select from what is available and integrate it with your existing pipeline.

“This sounds expensive.”

Data contracts are not free. Author time, tooling costs, and ongoing maintenance are real. But the cost has to be compared to the cost of silent breakage, which in pharma is not hypothetical. If a single downstream failure caused by an uncommunicated schema change costs you a re-submission delay, a warning letter response, or a validated re-testing cycle, you have already paid more than the contract program would have cost. The math on data contracts in regulated industries is easier than the math in unregulated industries, because the downside events are more expensive.

Where This Fits with ALCOA+, EU AI Act, and ICH E6(R3)

Data contracts do not appear by name in any current pharma regulation. But their components map cleanly onto requirements that are explicit in current regulatory frameworks.

ALCOA+ Alignment

The ALCOA+ principles require data to be Attributable, Legible, Contemporaneous, Original, Accurate, and (in the “plus” extensions) Complete, Consistent, Enduring, and Available13. Data contracts contribute to each of these:

  • Attributable: Ownership section names accountable producer and consumer teams.
  • Contemporaneous: SLA section commits to freshness expectations.
  • Original: Change management protocol prevents unversioned overwrites.
  • Accurate: Quality guarantees define measurable accuracy thresholds.
  • Complete: Schema and quality sections define completeness requirements.
  • Consistent: Schema versioning enforces consistency across loads.

Draft EU GMP Chapter 4 (published July 2025) formalizes ALCOA++ requirements into regulation11. Organizations that already have data contracts on their GxP-adjacent data flows will find themselves closer to compliance than those that do not.

EU AI Act Alignment

The EU AI Act’s high-risk AI system requirements (Article 10) explicitly mandate that training, validation, and testing datasets be relevant, sufficiently representative, and free of errors to the greatest extent possible9. Article 12 requires automatic recording of events (logs) relevant to identifying risks and enabling post-market monitoring. Both of these are difficult to demonstrate without contracts on the data flows feeding the AI system. Organizations building AI systems that will be classified as high-risk (many pharma AI applications fall into this category) should be planning for a data contract layer as part of their AI compliance architecture, not as an optional add-on.

ICH E6(R3) Alignment

ICH E6(R3), finalized in January 2025, includes explicit language on data governance for clinical trials12. The guideline requires sponsors to have appropriate systems and processes to ensure the quality, integrity, and reliability of clinical trial data across the data life cycle. This life-cycle framing maps directly onto the data contract concept: producers (sites, CROs, EDC vendors) and consumers (data managers, biostatisticians, medical writers) need a shared understanding of what data will be delivered, how it will be structured, and how changes will be managed. That shared understanding is what a data contract encodes.

The regulatory bottom line: Data contracts are not required by any current regulation, but the trajectory of pharma data regulation is toward the kind of documented, traceable, controlled data flows that contracts happen to produce. Organizations that adopt contracts now are moving toward the regulatory direction of travel. Organizations that delay will find themselves retrofitting.

Conclusion

Data contracts are not a silver bullet for pharma data quality. They will not fix upstream source system issues, they will not eliminate the need for human judgment about data semantics, and they will not survive an organization that is not willing to hold producers and consumers to written commitments. What they do is solve the specific problem of silent breakage at the producer-consumer boundary, which is where a disproportionate share of pharma data integrity failures originate.

The case for adopting data contracts in pharma rests on three converging pressures: the volume and velocity of downstream data consumption is outrunning human quality control; the regulatory frameworks that govern pharma data are trending toward the kind of documented, enforceable data flows that contracts produce; and the AI use cases that pharma organizations are increasingly betting on cannot function reliably on data flows that break silently. Any one of these pressures would justify starting the work. Together, they make the delay itself expensive.

The right starting point is not a comprehensive rollout. It is a single high-consequence data product with a single consumer team, an honestly-authored contract that reflects what the system currently delivers, and automated enforcement that catches drift at the boundary rather than in the downstream. From there, the pattern spreads if it is delivering value, and does not spread if it is not. The pilot is what tells you which one you have.

Sakara Digital works with pharma and biotech organizations building this kind of foundational data infrastructure. If you are exploring data contracts as part of a broader data quality or AI-readiness initiative and want an independent perspective on where to start, we are happy to have that conversation.